not used title
not used title
PhRMA announced last week that member companies, thanks to President Trump’s new tax law and regulatory streamlining, are investing $500 billion in new U.S.-based manufacturing and infrastructure, injecting $1.2 trillion into the U.S. economy and creating over 100,000 new jobs, including at least 25,000 direct biopharmaceutical jobs. Member companies also announced they are providing 10 million patients with financial assistance annually and the creation of AmericasMedicines.com, a search engine to connect patients and businesses with manufacturer direct purchase programs, launching in January 2026.
Celebrating American workers
October is Manufacturing Month, and it is a time to recognize the vital role manufacturing plays in America’s economy and global leadership, but also the hard work of the men and women who make it possible. Every year, the American biopharmaceutical industry makes significant investments in manufacturing, a critical component to delivering medicines to patients.
By the numbers
Manufacturing medicines and vaccines helps grow the economy and employs high-skilled workers across the country. Today, biopharmaceutical companies in America provide:
- 1,500+ facilities in 48 states manufacturing innovative medicines
- 5 million high-skilled jobs, including one million direct industry employees
- $1.6 trillion in economic impact added to the American economy every year
Not only is our industry strengthening America’s biomanufacturing capabilities, but companies like Bristol Myers Squibb, Amgen, Astellas, Gilead and AstraZeneca are breaking ground, opening new sites and growing to deliver tomorrow’s breakthrough medicines.
Bad policy threatens these investments
As we recognize the vital role manufacturing plays in ensuring innovative treatments make it to patients, we need a policy environment that supports investment in manufacturing and strengthens America’s world-leading innovation ecosystem.
Learn how the biopharmaceutical industry is committed to investing in domestic manufacturing and making medicines in America.
Drew Voytal
Drew Voytal, MPA is a Senior Director of public affairs at PhRMA focusing on advocacy and policy communications on key issues, including 340B. His career in health care advocacy, policy and public affairs spans more than a decade in Washington, DC where he has built relationships with key government and industry partners to advance public policy priorities. Drew has personally experienced the benefits of biopharmaceutical research and innovation and is passionate about telling the story of this vital industry.
Drew Voytal
Staffing up: Building the future biopharma workforce to keep America in the lead
June 29, 2026
Nearly 80 researchers advocate on Capitol Hill
June 11, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
America Cures: Championing U.S. leadership in medical innovation
February 18, 2026
Congratulations to our 2026 Working for Cures Employee Champions
January 29, 2026
Middlemen mark up drug prices and keep discounts meant for you
November 10, 2025
Celebrating STEM Day: Investing in America’s innovators
November 8, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Bringing to life the full story of biopharmaceutical innovation and investments
July 22, 2025
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
April 30, 2025
From sound to science: How IP powers innovation in music and hearing
April 25, 2025
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
March 12, 2025
New research: Industry sponsored clinical trials contribute billions to state economies
March 6, 2025
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
Biopharmaceutical industry supports jobs and drives economic growth across the United States
May 16, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
November 29, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
September 5, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New data: America is an API powerhouse
June 16, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
Biopharmaceutical manufacturing companies continue to expand their economic footprint across the United States
May 24, 2023
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
May 18, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
U.S. biopharmaceutical exports support jobs, innovation
March 20, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
December 8, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Congratulations to our 2022 Working for Cures Employee Champions
November 10, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
July 29, 2022
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
July 18, 2022
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
July 14, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
Biopharmaceutical researchers to discuss the value of R&D with Congress
June 9, 2022
A conversation with Barry Greene, CEO of Sage Therapeutics
May 4, 2022
Stephanie Dyson of BMS on reducing health disparities
April 27, 2022
Biopharmaceutical industry drives economic growth in all 50 states
March 14, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
November 1, 2021
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
September 28, 2021
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
September 27, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
July 22, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
Watch: Building trust and enhancing clinical trial diversity
June 24, 2021
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
June 23, 2021
Researchers to shine light on biopharmaceutical R&D with policymakers
June 15, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
March 5, 2021
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
February 24, 2021
Beyond output and employment: The impact of America’s biopharmaceutical industry
February 11, 2021
Preserving U.S. innovation worldwide is more important than ever
January 29, 2021
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
January 28, 2021
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
December 21, 2020
Report highlights biopharmaceutical industry’s commitment to D&I
December 17, 2020
Guest Post: Bringing our best to the fight against COVID-19
December 3, 2020
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
November 18, 2020
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
October 28, 2020
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
October 12, 2020
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
October 2, 2020
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
October 1, 2020
Leading researchers to spotlight the critical role of biopharmaceutical R&D
October 1, 2020
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
September 23, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
September 16, 2020
PhRMA member companies invested $83 billion in research and development last year
September 10, 2020
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
September 2, 2020
Three ways the pharmaceutical industry can positively impact health equity
September 1, 2020
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
August 4, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
July 16, 2020
In combating COVID-19, science is how we get back to normal
June 24, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
June 11, 2020
America’s global leadership in biopharmaceutical manufacturing
June 4, 2020
Guest Post: What will we learn from COVID-19?
May 27, 2020
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
May 21, 2020
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
May 14, 2020
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
April 15, 2020
To the millions affected by COVID-19
April 9, 2020
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
April 6, 2020
The biopharmaceutical industry’s unique role in responding to COVID-19
April 2, 2020
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
April 1, 2020
COVID-19 Response: Supporting the frontline
March 30, 2020
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
March 26, 2020
America’s biopharmaceutical companies are working around the clock to beat coronavirus
March 20, 2020
Guest post: Takeda’s efforts to address COVID-19
March 19, 2020
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
March 16, 2020
ICYMI: Continued biopharmaceutical action on COVID-19
March 6, 2020
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
February 12, 2020
Working together to combat coronavirus
February 6, 2020
What you need to know about H.R. 3
December 12, 2019
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
December 5, 2019
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
November 4, 2019
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
October 31, 2019
Pelosi’s radical plan leaves lung cancer patients behind
October 23, 2019
Event tomorrow: Maintaining America’s leadership in access and innovation
October 16, 2019
Pelosi’s radical plan would leave Alzheimer’s patients behind
October 16, 2019
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
October 10, 2019
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
October 4, 2019
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
September 26, 2019
World Trade Month: How we can expand world-class pro-innovation standards
May 22, 2019
New Report: Advanced manufacturing powering innovative biopharmaceuticals
May 10, 2019
Clinical trials impact state economies
May 3, 2019
Biopharmaceutical venture capital is spurring innovation and economic growth
February 11, 2019
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
August 9, 2018
Researchers bring focus on science and medicine to California’s capital city
May 29, 2018
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
May 10, 2018
New Report: America's biopharmaceutical industry supports 4.7 million jobs
March 1, 2018
Biopharma leads sustained economic growth driven by IP-intensive industries
September 26, 2017
The journey to better health care requires a holistic view
September 18, 2017
Helping those affected by the 2017 hurricane season
August 31, 2017
New PhRMA resources chock full of biopharma industry facts
July 20, 2017
New medicines are part of the solution to hold down future health care costs
June 28, 2017
Celebrating PRIDE in biopharmaceutical science
June 1, 2017
Guest Post: The importance of a modern FDA in drug discovery
March 22, 2017
Exploring the new era of medicine
February 21, 2017
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
February 15, 2017
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
February 14, 2017
Manufacturing
Economic Impact
PhRMA Member Company
Manufacturing U.S. jobs and breakthroughs
October 6, 2025